References
- RachakondaTDSchuppCWArmstrongAWPsoriasis prevalence among adults in the United StatesJ Am Acad Dermatol201470351251624388724
- KimballABJacobsonCWeissSVreelandMGWuYThe psychosocial burden of psoriasisAm J Clin Dermatol20056638339216343026
- MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
- NickoloffBJNestleFORecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunitiesJ Clin Invest2004113121664167515199399
- PuigLThe role of IL 23 in the treatment of psoriasisExpert Rev Clin Immunol201713652553428165883
- TonelGConradCLaggnerUCutting edge: a critical functional role for IL-23 in psoriasisJ Immunol2010185105688569120956338
- LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med2004199112513014707118
- NestleFOKaplanDHBarkerJPsoriasisN Engl J Med2009361549650919641206
- FitchEHarperESkorchevaIKurtzSEBlauveltAPathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokinesCurr Rheumatol Rep20079646146718177599
- PappKThaçiDReichKTildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialBr J Dermatol2015173493093926042589
- LevinAAGottliebABSpecific targeting of interleukin-23p19 as effective treatment for psoriasisJ Am Acad Dermatol201470355556124373779
- LowesMARussellCBMartinDATowneJEKruegerJGThe IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responsesTrends Immunol201334417418123291100
- KoppTRiedlEBangertCClinical improvement in psoriasis with specific targeting of interleukin-23Nature2015521755122222625754330
- ChanJRBlumenscheinWMurphyEIL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesisJ Exp Med2006203122577258717074928
- PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med2017376161551156028423301
- YangEJBeckKMLiaoWTildrakizumab-asmn: What’s in a Name?Am J Clin Dermatol201819329129229687361
- Tildrakizumab US prescribing information2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdfAccessed April 21, 2018
- AckermanABBoerABenninBHistologic Diagnosis of Inflammatory Skin Diseases: An Algorithmic Method Based on Pattern Analysis3rd edNew York, NYArdor Scribendi2005
- ReichKPappKABlauveltATildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsLancet20173901009127628828596043
- BlauveltAPappKAGriffithsCEEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialJ Am Acad Dermatol201776340541728057360
- ReichKArmstrongAWFoleyPEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialJ Am Acad Dermatol201776341843128057361
- PappKAReichKPaulCA prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisBr J Dermatol2016175227328626914406
- BlauveltAPappKALebwohlMGRapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAG-INE-2 and AMAGINE-3J Am Acad Dermatol201777237237428711089
- LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
- GordonKBBlauveltAPappKAPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535627299809